DR. DAVID JARVIS
National Medical Director for the Select Medical Corporation Lawsuits, state inspection reports and statistics deep in federal reports paint a troubling picture of the care offered at some long-term care hospitals.
Federal prosecutors charged 14 hedge fund employees, lawyers and other investors in criminal complaints that seem to be connected to the Raj Rajaratnam case.
A regulatory overhaul of the financial industry faces difficulty in Congress, but unless the industry’s risks are addressed they could cause an even bigger crisis.
A regulatory overhaul of the financial industry faces difficulty in Congress, but unless the industry’s risks are addressed they could cause an even bigger crisis.
At least four million Americans are exposed to high doses each year, and about 400,000 patients receive more than the maximum annual exposure allowed for nuclear power plant employees.
Eli Lilly has agreed to pay $62 million to 33 states to settle claims that it improperly marketed Zyprexa to patients who did not have schizophrenia or bipolar disorder.
Eli Lilly has agreed to pay $62 million to 33 states to settle claims that it improperly marketed Zyprexa to patients who did not have schizophrenia or bipolar disorder.
The major victories for Merck pushed the litigation over Vioxx closer to conclusion and highlighted the difficulty that plaintiffs’ lawyers are having in winning lawsuits against big drug companies.
The major victories for Merck pushed the litigation over Vioxx closer to conclusion and highlighted the difficulty that plaintiffs’ lawyers are having in winning lawsuits against big drug companies.
The prospect of a pending Supreme Court case that could sweep away many lawsuits against drug companies loomed over Alaska’s $15 million settlement with Eli Lilly.
The drug company has agreed to pay $15 million to the state of Alaska to settle a lawsuit claiming that its schizophrenia drug Zyprexa caused patients to develop diabetes.
The drug company has agreed to pay $15 million to the state of Alaska to settle a lawsuit claiming that its schizophrenia drug Zyprexa caused patients to develop diabetes.
John C. Lechleiter’s 2003 e-mail message appears to have encouraged Eli Lilly to promote its schizophrenia medicine Zyprexa for a use not approved by federal drug regulators.
Lilly hid Zyprexa’s risks, such as the possibility of causing severe weight gains and blood sugar changes, from doctors to protect the drug’s sales, an expert witness told jurors on Friday.
The state is asking the drug maker to pay for the medical expenses of Medicaid patients who have contracted diabetes or other diseases after taking the drug Zyprexa.